News
Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...
Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...
10h
MarketBeat on MSNSarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesIn another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular ...
Investing.com-- TD Cowen downgraded its rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) and slashed its price target ...
In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.
I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...
6h
Investor's Business Daily on MSNGilead Sciences Wins Approval For Highly Effective HIV Prevention DrugGilead Sciences won Food and Drug Administration approval Wednesday for a highly effective drug to prevent HIV infection.
Annual event brings together 1,200 plus families, physicians, researchers, caregivers, industry partners, and those living with Duchenne and Becke ...
Gilead has won FDA approval for an HIV prevention shot that is administered only once every six months. When will low-income ...
President Javier Milei's severe budget cuts to Argentina's public health system have led to a decline in care, particularly affecting cancer patients, according to experts, government workers and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results